134 related articles for article (PubMed ID: 28793068)
1. Incorporation of new medicines by the National Commission for Incorporation of Technologies, 2012 to June 2016.
Caetano R; Silva RMD; Pedro ÉM; Oliveira IAG; Biz AN; Santana P
Cien Saude Colet; 2017 Aug; 22(8):2513-2525. PubMed ID: 28793068
[TBL] [Abstract][Full Text] [Related]
2. Incorporation of drugs for rare diseases in Brazil: is it possible to have full access to these patients?
Biglia LV; Mendes SJ; Lima TM; Aguiar PM
Cien Saude Colet; 2021 Nov; 26(11):5547-5560. PubMed ID: 34852089
[TBL] [Abstract][Full Text] [Related]
3. [The incorporation of nusinersen by the Brazilian Unified National Health System: critical thoughts on the institutionalization of health technology assessment in Brazil].
Caetano R; Hauegen RC; Osorio-de-Castro CGS
Cad Saude Publica; 2019 Aug; 35(8):e00099619. PubMed ID: 31483045
[TBL] [Abstract][Full Text] [Related]
4. [Does the pharmaceutical industry interfere in the sustainability of the public health system in Brazil? A reflection on the pressure for the incorporation of medicines].
Tamachiro ST; Gonçalves FAR; Simone ALM; Aguiar PM
Cad Saude Publica; 2022; 38(7):e00233321. PubMed ID: 35894368
[TBL] [Abstract][Full Text] [Related]
5. Challenges to decision-making processes in the national HTA agency in Brazil: operational procedures, evidence use and recommendations.
Yuba TY; Novaes HMD; de Soárez PC
Health Res Policy Syst; 2018 May; 16(1):40. PubMed ID: 29751764
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of medicines in the Unified Health System (SUS): comparison between oncology and the specialized component of pharmaceutical care.
Capucho HC; Brito A; Maiolino A; Kaliks RA; Pinto RP
Cien Saude Colet; 2022 Jun; 27(6):2471-2479. PubMed ID: 35649033
[TBL] [Abstract][Full Text] [Related]
7. The regulation and adoption of health technologies under Brazil's Unified Health System: barriers to access to medicines for diseases of poverty?
Santana RS; Lupatini EO; Leite SN
Cien Saude Colet; 2017 May; 22(5):1417-1428. PubMed ID: 28538914
[TBL] [Abstract][Full Text] [Related]
8. [Use of health technology assessment in decision-making processes by the Brazilian Ministry of Health on the incorporation of technologies in the Brazilian Unified National Health System].
Novaes HM; Elias FT
Cad Saude Publica; 2013 Nov; 29 Suppl 1():S7-16. PubMed ID: 25402252
[TBL] [Abstract][Full Text] [Related]
9. Health technology reassessment in the Brazilian public health system: Analysis of the current status.
Pereira VC; Barreto JOM; Neves FADR
PLoS One; 2019; 14(7):e0220131. PubMed ID: 31356609
[TBL] [Abstract][Full Text] [Related]
10. Reversal of the recommendations issued by the National Commission for the Incorporation of Technologies in SUS after Public Consultations.
Lopes SGP; Luiza VL; Silva RMD
Cien Saude Colet; 2023 Feb; 28(2):561-573. PubMed ID: 36651407
[TBL] [Abstract][Full Text] [Related]
11. Health technology assessment in Brazil - an international perspective.
Lima SGG; Brito C; Andrade CJC
Cien Saude Colet; 2019 May; 24(5):1709-1722. PubMed ID: 31166506
[TBL] [Abstract][Full Text] [Related]
12. Exploring the COVID-19 Pandemic's Impact on the Health Technology Assessment Process of the National Commission for the Incorporation of Technologies Into the Brazilian Health System.
Cardoso MMA; Thabane L; Andrade LGM; Curado DDSP; Komoda DS; Machado-Rugolo J; Lima SAM; Weber SAT
Value Health Reg Issues; 2023 Sep; 37():18-22. PubMed ID: 37196546
[TBL] [Abstract][Full Text] [Related]
13. [Multi-criteria decision analysis for health technology resource allocation and assessment: so far and so near?].
Campolina AG; Soárez PC; Amaral FVD; Abe JM
Cad Saude Publica; 2017 Oct; 33(10):e00045517. PubMed ID: 29091169
[TBL] [Abstract][Full Text] [Related]
14. [Judicialization of access to medicines: analysis of lawsuits in the state of Rio Grande do Norte, Brazil].
Oliveira YMDC; Braga BSF; Farias AD; Vasconcelos CM; Ferreira MAF
Cad Saude Publica; 2021; 37(1):e00174619. PubMed ID: 33440411
[TBL] [Abstract][Full Text] [Related]
15. Social participation in the health technology incorporation process into Unified Health System.
Silva AS; Sousa MSA; Silva EVD; Galato D
Rev Saude Publica; 2019; 53():109. PubMed ID: 31859904
[TBL] [Abstract][Full Text] [Related]
16. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
17. Decision criteria for resource allocation: an analysis of CONITEC oncology reports.
Campolina AG; Yuba TY; Soárez PC
Cien Saude Colet; 2022 Jul; 27(7):2563-2572. PubMed ID: 35730828
[TBL] [Abstract][Full Text] [Related]
18. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
19. Health technology assessment and judicial deference to priority-setting decisions in healthcare: Quasi-experimental analysis of right-to-health litigation in Brazil.
Wang D; Vasconcelos NP; Poirier MJ; Chieffi A; Mônaco C; Sritharan L; Van Katwyk SR; Hoffman SJ
Soc Sci Med; 2020 Nov; 265():113401. PubMed ID: 33250316
[TBL] [Abstract][Full Text] [Related]
20. Analysis of new drugs registered in Brazil in view of the Unified Health System and the disease burden.
Botelho SF; Martins MAP; Reis AMM
Cien Saude Colet; 2018 Jan; 23(1):215-228. PubMed ID: 29267825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
